On February 2, 2024, Cingulate Inc., a biopharmaceutical company, announced the pricing of a public offering expected to raise $7.5 million. The offering, which closed on February 6, 2024, included 3,750,000 shares of common stock, Series A warrants to purchase up to 3,750,000 shares, and Series B warrants to purchase up to 1,875,000 shares, with each share and accompanying warrants priced at $2.00. The Series A warrants are exercisable immediately and expire in five years, while the Series B warrants also exercisable immediately, expire in two years. The company intends to use the net proceeds for research and development, commercialization of its lead candidate CTx-1301, and other corporate purposes. The offering was made under a registration statement declared effective by the SEC on February 2, 2024. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

On February 2, 2024, Cingulate Inc., a biopharmaceutical company, announced the pricing of a public offering expected to raise $7.5 million. The offering, which closed on February 6, 2024, included 3,750,000 shares of common stock, Series A warrants to purchase up to 3,750,000 shares, and Series B warrants to purchase up to 1,875,000 shares, with each share and accompanying warrants priced at $2.00. The Series A warrants are exercisable immediately and expire in five years, while the Series B warrants also exercisable immediately, expire in two years. The company intends to use the net proceeds for research and development, commercialization of its lead candidate CTx-1301, and other corporate purposes. The offering was made under a registration statement declared effective by the SEC on February 2, 2024. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.